{"type":"trials","record":{"id":41931,"source_id":"clinicaltrials-gov","external_id":"NCT04597632","title":"An Extension Study Assessing the Efficacy and Safety of Brolucizumab in a Treat-to-Control Regimen in Patients With Neovascular Age-related Macular Degeneration Who Have Completed the CRTH258A2303 (TALON) Study","brief_summary":"The purpose of this extension study was to evaluate the efficacy and safety of brolucizumab used in a Treat-to-Control-regimen for treatment of patients with neovascular age-related macular degeneration who have completed the CRTH258A2303 (TALON) study. The main objective was to assess brolucizumab's potential for long durability up to 20 weeks. All eligible participants were treated with brolucizumab regardless of their treatment in the TALON study. The study period was 56 weeks including post-treatment follow-up.","overall_status":"Completed","phases":["PHASE3"],"study_type":"INTERVENTIONAL","sponsor":"Novartis Pharmaceuticals","enrollment":248,"countries":["United States","Australia","Belgium","Czechia","France","Germany","Israel","Italy","Malaysia","Netherlands","Portugal","South Korea","Spain","Sweden","Switzerland","Taiwan"],"start_date":"2020-12-16","completion_date":"2023-03-28","last_update_date":"2024-10-09","source_url":"https://clinicaltrials.gov/study/NCT04597632","editorial_summary":"A registered PHASE3 study indexed because it matched monitored longevity research terms. Registry status: Completed. Registration does not establish safety or effectiveness.","first_seen_at":"2026-09-25T01:25:30.378222+00:00","last_seen_at":"2026-09-25T06:20:47.789+00:00","metadata":{"sex":"ALL","acronym":"TALON Ext","age_range":"50 Years","comparator":null,"organization":"Novartis","interventions":["brolucizumab"],"registry_source":"ClinicalTrials.gov","outcome_measures":["Duration of the Last Interval With no Disease Activity up to Week 56 - Study Eye — Up to Week 56","Average Change in BCVA From Baseline to Week 52 and Week 56 for the Study Eye — Extension study baseline, average of We…","Average Change in Central Subfield Thickness (CSFT) From Baseline to Week 52 and Week 56 - Study Eye — Extension study…","Number (%) of Subjects With Presence of IRF and/or SRF, and Sub-RPE Fluid in the Study Eye at Week 52 and Week 56 Overa…","Last Interval With no Disease Activity (Number of Weeks): Number (%) of Subjects at 20/16/12/8/4-weeks Intervals up to…","Maximal Interval With no Disease Activity (Number of Weeks): Number (%) of Subjects at 20/16/12/8/4-weeks Intervals up…","Number (%) of Subjects With Change in Duration of Last Interval With no Disease Activity Between Baseline of the Extens…","Treatment-emergent Ocular Adverse Events (Greater Than or Equal to 1.0%) by Preferred Term for the Study Eye — Adverse…","Treatment-emergent Non-ocular Adverse Events (Greater Than or Equal to 2%) by Preferred Term — Adverse events are repor…"],"design_description":"NA · SINGLE GROUP · TREATMENT · NONE","source_has_results":true},"controlled_terms":["Neovascular Age-related Macular Degeneration","brolucizumab"],"relevance_confidence":100,"source_quality_score":100,"freshness_score":65,"publication_state":"published","match_explanation":"Title contains controlled term: age-related macular degeneration.","quality_checked_at":"2026-09-25T06:20:59.355028+00:00","duplicate_cluster_key":"id:nct04597632","duplicate_of_id":null,"evidence_snapshot":{"status":"structured","version":1,"duration":"2020-12-16 to 2023-03-28","comparator":null,"confidence":"structured-source","population":"ALL · 50 Years","provenance":{"duration":"start_date and completion_date","comparator":"registry arm fields","population":"registry eligibility fields","intervention":"registry intervention fields","participants":"enrollment","study_design":"study_type and registry design fields","evidence_stage":"phases","reported_outcome":"not available","outcomes_measured":"registry outcome-measure fields"},"generated_at":"2026-09-25T06:20:47.894Z","intervention":["brolucizumab"],"participants":248,"study_design":"NA · SINGLE GROUP · TREATMENT · NONE","subject_scope":"Human clinical study registration","evidence_stage":"PHASE3","safety_context":"Eligibility, adverse-event details, and clinical decisions must be checked in the official registry and with qualified clinicians.","source_support":"Structured registry protocol metadata; no finding-level conclusion is generated.","main_limitation":"This is a study registration. No reusable structured result is available here, so it cannot show whether the intervention worked or was safe.","reported_outcome":null,"outcomes_measured":["Duration of the Last Interval With no Disease Activity up to Week 56 - Study Eye — Up to Week 56","Average Change in BCVA From Baseline to Week 52 and Week 56 for the Study Eye — Extension study baseline, average of We…","Average Change in Central Subfield Thickness (CSFT) From Baseline to Week 52 and Week 56 - Study Eye — Extension study…","Number (%) of Subjects With Presence of IRF and/or SRF, and Sub-RPE Fluid in the Study Eye at Week 52 and Week 56 Overa…","Last Interval With no Disease Activity (Number of Weeks): Number (%) of Subjects at 20/16/12/8/4-weeks Intervals up to…","Maximal Interval With no Disease Activity (Number of Weeks): Number (%) of Subjects at 20/16/12/8/4-weeks Intervals up…","Number (%) of Subjects With Change in Duration of Last Interval With no Disease Activity Between Baseline of the Extens…","Treatment-emergent Ocular Adverse Events (Greater Than or Equal to 1.0%) by Preferred Term for the Study Eye — Adverse…","Treatment-emergent Non-ocular Adverse Events (Greater Than or Equal to 2%) by Preferred Term — Adverse events are repor…"],"regulatory_context":"Trial registration is not regulatory approval and does not establish that an intervention is available."},"clinical_trial_topics":[{"topic_slug":"vision-aging","is_published":true,"match_reasons":["Title contains controlled term: age-related macular degeneration.","Abstract contains controlled term: age-related macular degeneration.","Source terminology contains: age-related macular degeneration.","Title supplies longevity context: age-related.","Study type is explicitly identified as INTERVENTIONAL."],"matched_fields":["title","abstract","controlled terminology","title context","study type"],"relevance_score":100,"intelligence_topics":{"name":"Vision ageing","slug":"vision-aging"}}],"content_sources":{"name":"ClinicalTrials.gov","homepage_url":"https://clinicaltrials.gov/"}},"canonical_url":"https://www.immortal.life/trials/41931","automation_disclosure":"Generated automatically from cited source metadata. No scientist, clinician, researcher, editor, or human reviewer evaluates this publication before release."}